SG10202111952PA - Combination therapy with controlled-release cnp agonists - Google Patents
Combination therapy with controlled-release cnp agonistsInfo
- Publication number
- SG10202111952PA SG10202111952PA SG10202111952PA SG10202111952PA SG10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA SG 10202111952P A SG10202111952P A SG 10202111952PA
- Authority
- SG
- Singapore
- Prior art keywords
- controlled
- combination therapy
- release cnp
- cnp agonists
- agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191456 | 2016-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111952PA true SG10202111952PA (en) | 2021-12-30 |
Family
ID=57047055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111952PA SG10202111952PA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
| SG11201901534VA SG11201901534VA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901534VA SG11201901534VA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11564974B2 (en) |
| EP (2) | EP4223309A1 (en) |
| JP (1) | JP7189133B2 (en) |
| KR (2) | KR20230066147A (en) |
| CN (1) | CN109843295B (en) |
| AU (2) | AU2017336253B2 (en) |
| BR (1) | BR112019005351A2 (en) |
| CA (1) | CA3037448A1 (en) |
| DK (1) | DK3518930T3 (en) |
| ES (1) | ES2943013T3 (en) |
| FI (1) | FI3518930T3 (en) |
| HR (1) | HRP20230385T1 (en) |
| HU (1) | HUE062117T2 (en) |
| IL (3) | IL305975A (en) |
| LT (1) | LT3518930T (en) |
| MA (1) | MA46430B1 (en) |
| MX (1) | MX2019003173A (en) |
| NZ (1) | NZ751746A (en) |
| PL (1) | PL3518930T3 (en) |
| PT (1) | PT3518930T (en) |
| RS (1) | RS64203B1 (en) |
| RU (1) | RU2768747C2 (en) |
| SG (2) | SG10202111952PA (en) |
| SI (1) | SI3518930T1 (en) |
| WO (1) | WO2018060314A1 (en) |
| ZA (1) | ZA201901810B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
| IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| WO2017118703A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| CA3007979C (en) | 2016-01-08 | 2023-12-19 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| JP7051686B2 (en) * | 2016-01-08 | 2022-04-11 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | CNP prodrug with large carrier portion |
| KR102524255B1 (en) | 2016-03-01 | 2023-04-20 | 아센디스 파마 본 디지즈 에이/에스 | Pth prodrugs |
| US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| HRP20231079T1 (en) | 2016-09-29 | 2023-12-22 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
| ES2943720T3 (en) | 2016-09-29 | 2023-06-15 | Ascendis Pharma Bone Diseases As | PTH compounds with low peak-to-valley ratios |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
| AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CN1169573C (en) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides |
| JP4252746B2 (en) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | Treatment for achondroplasia |
| BRPI0203172B8 (en) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | pharmaceutical composition for achondroplasia |
| PT2279753E (en) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
| US7054679B2 (en) | 2001-10-31 | 2006-05-30 | Robert Hirsh | Non-invasive method and device to monitor cardiac parameters |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CN100558398C (en) | 2002-11-26 | 2009-11-11 | 拜奥康有限公司 | Natriuresis chemical compound, conjugate and the application thereof of modifying |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005099768A2 (en) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (en) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| EP2295445A1 (en) | 2006-09-08 | 2011-03-16 | Mayo Foundation for Medical Education and Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| KR20140032505A (en) | 2006-11-09 | 2014-03-14 | 알콘 리서치, 리미티드 | Water insoluble polymer matrix for drug delivery |
| KR20080098216A (en) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | Natriuretic peptide conjugate using carrier substance |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| JP2010533202A (en) | 2007-07-11 | 2010-10-21 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Polymeric drug delivery system comprising a polysubstituted aromatic moiety |
| US8377884B2 (en) | 2007-11-21 | 2013-02-19 | Biomarin Pharmaceutical Inc. | Variants of C-type natriuretic peptides |
| MX2010008024A (en) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker. |
| JP2011520983A (en) | 2008-05-23 | 2011-07-21 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Polymer systems containing intracellular releasable disulfide linkers for oligonucleotide delivery |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| HUE031840T2 (en) | 2009-02-03 | 2017-08-28 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| PT2432489T (en) | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variants of c-type natriuretic peptide |
| US11559482B2 (en) | 2009-07-31 | 2023-01-24 | Ascendis Pharma A/S | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| WO2011012722A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| ES2584381T3 (en) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| CN103025164B (en) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | The control release of medicine from solid support |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| US8989456B2 (en) | 2010-06-30 | 2015-03-24 | Nec Solution Innovators, Ltd. | Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system |
| KR101997939B1 (en) | 2011-08-12 | 2019-07-08 | 아센디스 파마 에이에스 | Carrier-linked treprostinil prodrugs |
| EP2741782B1 (en) | 2011-08-12 | 2020-05-06 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| CA2843506C (en) | 2011-08-12 | 2020-05-12 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| CA2843875C (en) | 2011-08-12 | 2020-01-07 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| AU2013254756B2 (en) | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| EP2853273A4 (en) | 2012-04-25 | 2016-01-13 | Daiichi Sankyo Co Ltd | Bone repair promoter |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| RU2647729C2 (en) | 2012-10-11 | 2018-03-19 | Асцендис Фарма Ас | Hydrocarbon gel-based prodrugs |
| WO2014060512A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Fatty acid acylated amino acids for growth hormone delivery |
| JP6536871B2 (en) * | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Preventive and therapeutic agent for FGFR3 disease and method of screening the same |
| CN106232141A (en) | 2014-02-27 | 2016-12-14 | 第三共株式会社 | For the medicine by the growth deficiency giving steroid induction |
| HUE053855T2 (en) | 2014-11-18 | 2021-07-28 | Ascendis Pharma Endocrinology Div A/S | Novel polymeric hgh prodrugs |
| SG11201705521YA (en) | 2015-01-09 | 2017-08-30 | Ascendis Pharma Growth Disorders As | Cnp prodrugs |
| CA3007315A1 (en) | 2015-12-08 | 2017-06-15 | Biomarin Pharmaceutical Inc. | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| JP7076371B2 (en) | 2016-01-08 | 2022-05-27 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | Sustained-release CNP agonist with increased NEP stability |
| WO2017118703A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| JP7051686B2 (en) | 2016-01-08 | 2022-04-11 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | CNP prodrug with large carrier portion |
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
| CA3007979C (en) | 2016-01-08 | 2023-12-19 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| KR102524255B1 (en) | 2016-03-01 | 2023-04-20 | 아센디스 파마 본 디지즈 에이/에스 | Pth prodrugs |
| US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| WO2020037285A1 (en) | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
| US20220118053A1 (en) | 2019-02-11 | 2022-04-21 | Ascendis Pharma Growth Disorders A/S | Dry Pharmaceutical Formulations of CNP Conjugates |
-
2017
- 2017-09-28 US US16/338,185 patent/US11564974B2/en active Active
- 2017-09-28 MX MX2019003173A patent/MX2019003173A/en unknown
- 2017-09-28 KR KR1020237015410A patent/KR20230066147A/en not_active Application Discontinuation
- 2017-09-28 LT LTEPPCT/EP2017/074596T patent/LT3518930T/en unknown
- 2017-09-28 JP JP2019516647A patent/JP7189133B2/en active Active
- 2017-09-28 HU HUE17781429A patent/HUE062117T2/en unknown
- 2017-09-28 SG SG10202111952PA patent/SG10202111952PA/en unknown
- 2017-09-28 BR BR112019005351A patent/BR112019005351A2/en unknown
- 2017-09-28 IL IL305975A patent/IL305975A/en unknown
- 2017-09-28 PL PL17781429.0T patent/PL3518930T3/en unknown
- 2017-09-28 ES ES17781429T patent/ES2943013T3/en active Active
- 2017-09-28 RS RS20230385A patent/RS64203B1/en unknown
- 2017-09-28 FI FIEP17781429.0T patent/FI3518930T3/en active
- 2017-09-28 CN CN201780058524.8A patent/CN109843295B/en active Active
- 2017-09-28 NZ NZ751746A patent/NZ751746A/en unknown
- 2017-09-28 DK DK17781429.0T patent/DK3518930T3/en active
- 2017-09-28 EP EP23159718.8A patent/EP4223309A1/en active Pending
- 2017-09-28 HR HRP20230385TT patent/HRP20230385T1/en unknown
- 2017-09-28 MA MA46430A patent/MA46430B1/en unknown
- 2017-09-28 AU AU2017336253A patent/AU2017336253B2/en active Active
- 2017-09-28 WO PCT/EP2017/074596 patent/WO2018060314A1/en unknown
- 2017-09-28 SG SG11201901534VA patent/SG11201901534VA/en unknown
- 2017-09-28 PT PT177814290T patent/PT3518930T/en unknown
- 2017-09-28 EP EP17781429.0A patent/EP3518930B1/en active Active
- 2017-09-28 IL IL290054A patent/IL290054B2/en unknown
- 2017-09-28 CA CA3037448A patent/CA3037448A1/en active Pending
- 2017-09-28 SI SI201731339T patent/SI3518930T1/en unknown
- 2017-09-28 RU RU2019112897A patent/RU2768747C2/en active
- 2017-09-28 KR KR1020197012470A patent/KR102531327B1/en active IP Right Grant
-
2019
- 2019-03-25 IL IL265592A patent/IL265592B/en unknown
- 2019-03-25 ZA ZA2019/01810A patent/ZA201901810B/en unknown
-
2022
- 2022-12-22 US US18/145,676 patent/US20230302091A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201709A patent/AU2023201709A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290054A (en) | Combination therapy with controlled-release cnp agonists | |
| IL263521A (en) | Combination therapy | |
| HK1259384A1 (en) | Controlled-release cnp agonists with increased nep stability | |
| IL259658A (en) | Controlled-release cnp agonists with reduced side-effects | |
| IL259827A (en) | Controlled-release cnp agonists with low initial npr-b activity | |
| IL265406B (en) | Combination therapy | |
| GB201608797D0 (en) | Therapeutic use | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| IL265340A (en) | Combination therapy | |
| GB201609735D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| GB201706227D0 (en) | Combination therapy | |
| GB201706232D0 (en) | Combination therapy | |
| GB201706231D0 (en) | Combination therapy | |
| GB201706230D0 (en) | Combination therapy | |
| GB201706222D0 (en) | Combination therapy | |
| GB201706223D0 (en) | Combination therapy | |
| GB201706229D0 (en) | Combination therapy | |
| GB201706221D0 (en) | Combination therapy | |
| GB201706224D0 (en) | Combination therapy | |
| GB201706226D0 (en) | Combination therapy | |
| GB201706228D0 (en) | Combination therapy | |
| GB201706225D0 (en) | Combination therapy | |
| GB201704286D0 (en) | Combination Therapy |